1Teresa A,Martin M.Vasopressin-receptor antagonists in heart failureAm J Health Syst Pharm,2009,65:807-817. 被引量：1
2Chandrashekhar Y,Prahash A J,Sen S,et al.The role of arginine vasopressin and its receptors in the normal and failing rat heart.J Mol Cell Cardiol,2003,35:495-504. 被引量：1
3Gheorghiade M,Niazi I,Ouyang J,et al.Vasopressin V2-rceptor blockade with tolvaptan in patients with chronic heart failure:results from a double-blind,randomized trial.Cireutatiou,2005,t07 (2 t):2690-2696. 被引量：1
5Udelson JE,Orlandi C,O Brien T,et al.Vasopressin receptor blockade in patients with congestive heart failure; results from a placebo-controlled,randomized study comparing the effects of tolvaptan,furosemide,and their combination.J Am Coil Cardiol,2006,39:810. 被引量：1
6Costello-Boerrigter LC,Smith WB,Boerrigter G,et al.Vasopressin2receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.Am J Physiol Renal Physiol,2006,290:F273-278. 被引量：1
7Udelsoo JE,McGrew F,Flores E.Multiceuter,randomized,doubleblind.Placebo-controlled study on the effect of 0ral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.J Am Coll Cardiol,2007,49:2151-2159. 被引量：1
9Gheorghiade M,Orlandi C,Bumett JC,et al.Rationale and design ofthe multicenter,randomized,double-blind,placebo-controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure:Outcome Study with Tolvaptan(EVER-EST).J Card Fail,2005,11:260-269. 被引量：1
2Chandrashekhar Y,Prahash AJ,Sen S,et al.The role of arginine vasopressin and its receptors in the normal and failing rat heart[J].J Mol Cell Cardiol,2003,35(5):495-504. 被引量：1
3Gheorghiade M,Niazi I,Ouyang J,et al.Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure:results from a double-blind,randomized trial[J].Circulation,2003,107(21):2690-2696. 被引量：1
4Gheorghiade M,Gattis WA,O′Connor CM,et al.Effects of tolvaptan a vasopressin antagonist,in patients hospitalized with worsening heart failure:a randomized controlled trial[J].JAMA,2004,291(16):1963-1971. 被引量：1
5Udelson JE,Orlandi C,O′Brien T,et al.Vasopressin receptor blockade in patients with congestive heart failure;results from a placebo-controlled,randomized study comparing the effects of tolvaptan,furosemide,and their combination[J].J Am Coll Cardiol,2002,39(suppl A):810. 被引量：1
6Costello-Boerrigter LC,Smith WB,Boerrigter G,et al.Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure[J].Am J Physiol Renal Physiol,2006,290(2):F273-278. 被引量：1
7Udelson JE,McGrew F,Flores E,et al.Multicenter,randomized,double-blind,placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction[J].J Am Coll Cardiol,2007,49(22):2151-2159. 被引量：1
8Gheorghiade M,Orlandi C,Burnett JC,et al.Rationale and design of the multicenter,randomized,double-blind,placebo-controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure:Outcome Study with Tolvaptan(EVEREST)[J].J Card Fail,2005,11(4):260-269. 被引量：1
9Gheorghiade M,Konstam MA,Burnett JC Jr,et al.Short-term clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure:the EVEREST Clinical Status Trials[J].JAMA,2007,297(12):1332-1343. 被引量：1
10Konstam MA,Gheorghiade M,Burnett JC Jr,et al.Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST Outcome Trial[J].JAMA,2007,297(12):1319-1331. 被引量：1
